MX2010002427A - Inhibidores de actividad de la proteina tirosina cinasa. - Google Patents

Inhibidores de actividad de la proteina tirosina cinasa.

Info

Publication number
MX2010002427A
MX2010002427A MX2010002427A MX2010002427A MX2010002427A MX 2010002427 A MX2010002427 A MX 2010002427A MX 2010002427 A MX2010002427 A MX 2010002427A MX 2010002427 A MX2010002427 A MX 2010002427A MX 2010002427 A MX2010002427 A MX 2010002427A
Authority
MX
Mexico
Prior art keywords
tyrosine kinase
kinase activity
protein tyrosine
receptor signalling
inhibitors
Prior art date
Application number
MX2010002427A
Other languages
English (en)
Spanish (es)
Inventor
Tetsuyuki Uno
Franck Raeppel
Oscar Mario Saavedra
Lijie Zhan
Stephen William Claridge
Arkadii Vaisburg
Michael Mannion
Nancy Z Zhou
Ljubomir Isakovic
Raeppel Stephane
Frederic Gaudette
Robert Deziel
Original Assignee
Methylgene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Methylgene Inc filed Critical Methylgene Inc
Publication of MX2010002427A publication Critical patent/MX2010002427A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
MX2010002427A 2007-08-29 2008-08-28 Inhibidores de actividad de la proteina tirosina cinasa. MX2010002427A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96867307P 2007-08-29 2007-08-29
PCT/CA2008/001538 WO2009026717A1 (en) 2007-08-29 2008-08-28 Inhibitors of protein tyrosine kinase activity

Publications (1)

Publication Number Publication Date
MX2010002427A true MX2010002427A (es) 2010-03-30

Family

ID=40386626

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010002427A MX2010002427A (es) 2007-08-29 2008-08-28 Inhibidores de actividad de la proteina tirosina cinasa.

Country Status (19)

Country Link
US (3) US8404846B2 (enExample)
EP (1) EP2183254B1 (enExample)
JP (1) JP5656634B2 (enExample)
KR (1) KR101556269B1 (enExample)
CN (3) CN109970759A (enExample)
AR (1) AR068066A1 (enExample)
AU (1) AU2008293038B2 (enExample)
BR (1) BRPI0816064B8 (enExample)
CA (1) CA2697795C (enExample)
DK (1) DK2183254T3 (enExample)
ES (1) ES2635131T3 (enExample)
IL (1) IL204192A (enExample)
MX (1) MX2010002427A (enExample)
MY (1) MY156536A (enExample)
PL (1) PL2183254T3 (enExample)
RU (1) RU2495044C2 (enExample)
TW (1) TWI571468B (enExample)
WO (1) WO2009026717A1 (enExample)
ZA (1) ZA201001512B (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0908573A2 (pt) * 2008-03-05 2012-12-25 Methylgene Inc inibidores da atividade de proteÍna tirosina quinase
ES2599458T3 (es) * 2008-10-14 2017-02-01 Sunshine Lake Pharma Co., Ltd. Compuestos y métodos de uso
EP2408300B1 (en) * 2009-03-21 2016-05-11 Sunshine Lake Pharma Co., Ltd. Amino ester derivatives, salts thereof and methods of use
US9340555B2 (en) 2009-09-03 2016-05-17 Allergan, Inc. Compounds as tyrosine kinase modulators
MX2012002591A (es) * 2009-09-03 2012-04-02 Allergan Inc Compuestos como moduladores de tirosina cinasas.
TW201204735A (en) * 2010-04-16 2012-02-01 Methylgene Inc Inhibitors of protein tyrosine kinase activity
GB201007203D0 (en) 2010-04-29 2010-06-16 Glaxo Group Ltd Novel compounds
US20130315895A1 (en) 2010-07-01 2013-11-28 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
DK2621481T4 (da) * 2010-09-27 2023-01-09 Exelixis Inc Dobbelte inhibitorer af MET og VEGF til behandling af kastrationsresistent prostatacancer og osteoblastiske knoglemetastaser
JP2013537918A (ja) * 2010-09-27 2013-10-07 エクセリクシス， インク． 去勢抵抗性前立腺癌および骨芽細胞骨転移の治療のためのｍｅｔおよびｖｅｇｆの二元阻害薬
JP2013540759A (ja) * 2010-09-27 2013-11-07 エクセリクシス， インク． 去勢抵抗性前立腺癌および造骨性転移の治療のためのｍｅｔおよびｖｅｇｆの二元阻害薬
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
CN102827186A (zh) * 2011-06-16 2012-12-19 中国科学院上海药物研究所 一类吡啶并五元杂环衍生物及其制备方法和用途
WO2013038362A1 (en) 2011-09-15 2013-03-21 Novartis Ag 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase
WO2013166296A1 (en) 2012-05-02 2013-11-07 Exelixis, Inc. A dual met - vegf modulator for treating osteolytic bone metastases
CN103626761B (zh) * 2012-08-24 2015-07-29 上海医药工业研究院 苯并吡啶氮杂卓类化合物及其作为抗肿瘤药物的应用
GB201216018D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Pharmacologically active compounds
GB201314452D0 (en) 2013-08-13 2013-09-25 Ostara Biomedical Ltd Embryo implantation
TWI672141B (zh) 2014-02-20 2019-09-21 美商醫科泰生技 投予ｒｏｓ１突變癌細胞之分子
JP6744309B2 (ja) 2014-12-02 2020-08-19 イグニタ，インコーポレイテッド 神経芽細胞腫の治療のための併用
JP6864953B2 (ja) 2014-12-09 2021-04-28 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ａｘｌに対するヒトモノクローナル抗体
GB201501302D0 (en) 2015-01-27 2015-03-11 Ostara Biomedical Ltd Embryo implantation
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
GB201517523D0 (en) 2015-10-05 2015-11-18 Ostara Biomedical Ltd Methods and compositions for managing reproduction
CN108697661A (zh) 2015-12-18 2018-10-23 亚尼塔公司 用于治疗癌症的组合
CN108530464B (zh) * 2017-03-02 2020-10-27 深圳海王医药科技研究院有限公司 一种多靶点激酶抑制剂
CN110913842A (zh) 2017-07-19 2020-03-24 伊尼塔公司 包括恩曲替尼的药物组合物
US10180422B1 (en) 2017-08-22 2019-01-15 Scripps Health Methods of treating a neuroendocrine tumor
EP3697390A1 (en) 2017-10-17 2020-08-26 Ignyta, Inc. Pharmaceutical compositions and dosage forms
JP6955630B2 (ja) * 2018-03-08 2021-10-27 ウェルマーカー・バイオ・カンパニー・リミテッドＷｅｌｌｍａｒｋｅｒ Ｂｉｏ ＣＯ．， Ｌｔｄ． チエノピリジン誘導体およびそれを含む医薬組成物
US12103974B2 (en) 2018-05-23 2024-10-01 Beigene, Ltd. Anti-OX40 antibodies and methods of use
CN109384799B (zh) * 2018-11-12 2020-07-14 深圳海王医药科技研究院有限公司 一种多靶点激酶抑制剂化合物的晶型a及制备方法和含有其的药物组合物
KR20220059386A (ko) 2019-09-06 2022-05-10 웰마커바이오 주식회사 바이오마커 기반 치료용 조성물
CA3150267A1 (en) * 2019-09-10 2021-03-18 Stephane L. Raeppel Crystalline form of a multi-tyrosine kinase inhibitor, method of preparation, and use thereof
JP2023503229A (ja) * 2019-11-21 2023-01-27 ベイジーン リミテッド 抗ｏｘ４０抗体とマルチキナーゼ阻害剤とによる癌の治療
WO2021139717A1 (zh) * 2020-01-07 2021-07-15 南京明德新药研发有限公司 氘代噻吩并吡啶类化合物
EP4213844A4 (en) 2020-09-17 2024-11-20 Mirati Therapeutics, Inc. POLYTHERAPIES
TW202302597A (zh) * 2021-03-10 2023-01-16 美商米拉蒂醫療公司 多重酪胺酸激酶抑制劑之結晶鹽、其製備方法及用途
WO2022240802A1 (en) 2021-05-10 2022-11-17 Teva Pharmaceuticals International Gmbh Solid state forms of sitravatinib salts and processes for preparation thereof
WO2023155777A1 (en) * 2022-02-15 2023-08-24 Beigene (Suzhou) Co., Ltd. N- [ (6-bromopyridin-3-yl) methyl] -2-methoxyethan-1-amine salts and preparation thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7000A (en) * 1850-01-08 Smut-machine
US7019A (en) * 1850-01-15 Improvement in obstetrical supporters
US6143764A (en) 1995-11-07 2000-11-07 Kirin Beer Kabushiki Kaisha Quinoline and quinazoline derivatives inhibiting platelet-derived growth factor receptor autophosphorylation and pharmaceutical compositions containing the same
EP1506962B1 (en) 2000-10-20 2008-07-02 Eisai R&D Management Co., Ltd. Nitrogen-containing aromatic heterocycles
US6821987B2 (en) 2001-04-27 2004-11-23 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives having azolyl group
AU2002313249B2 (en) 2001-06-22 2008-08-21 Kirin Pharma Kabushiki Kaisha Quinoline derivative and quinazoline derivate inhibiting self-phosphorylation of hepatocytus proliferator receptor, and medicinal composition containing the same
CA2468989A1 (en) * 2001-12-07 2003-06-19 Daniel M. Schwartz Treatment for age-related macular degeneration
UA77303C2 (en) * 2002-06-14 2006-11-15 Pfizer Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
CL2003002287A1 (es) * 2002-11-25 2005-01-14 Wyeth Corp COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS
PL2392565T3 (pl) 2003-09-26 2014-08-29 Exelixis Inc Modulatory c-Met i sposoby stosowania
WO2005082855A1 (ja) 2004-02-27 2005-09-09 Eisai Co., Ltd. 新規ピリジン誘導体およびピリミジン誘導体（２）
EP1732543B1 (en) * 2004-03-15 2017-05-10 PTC Therapeutics, Inc. Tetracyclic carboline deratives for inhibiting angiogenesis
US7767689B2 (en) * 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
US20050288290A1 (en) 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
JP5096142B2 (ja) * 2004-07-30 2012-12-12 メチルジーン インコーポレイテッド Ｖｅｇｆレセプターおよびｈｇｆレセプターシグナル伝達の阻害剤
AU2006229343A1 (en) * 2005-03-28 2006-10-05 Kirin Pharma Kabushiki Kaisha Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-Met autophosphorylation inhibiting potency
JO2787B1 (en) * 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
ES2473341T3 (es) 2005-05-20 2014-07-04 Methylgene Inc Inhibidores de la se�alizaci�n del receptor del VEGF y del receptor del HGF
BRPI0610322B8 (pt) * 2005-05-20 2021-05-25 Methylgene Inc inibidores de sinalização de receptor de vegf e de receptor de hgf e composição farmacêutica
TW200740820A (en) * 2005-07-05 2007-11-01 Takeda Pharmaceuticals Co Fused heterocyclic derivatives and use thereof
EP1889836B1 (en) 2005-08-24 2013-06-12 Eisai R&D Management Co., Ltd. Novel pyridine derivative and pyrimidine derivative (3)
US8003662B2 (en) 2006-01-30 2011-08-23 Array Biopharma, Inc. Heterobicyclic thiophene compounds and methods of use
JP2009529047A (ja) 2006-03-07 2009-08-13 アレイ バイオファーマ、インコーポレイテッド ヘテロ二環系ピラゾール化合物およびその使用
AR060061A1 (es) * 2006-03-22 2008-05-21 Methylgene Inc Inhibidores de la actividad de la proteina tirosina quinasa
WO2007146824A2 (en) 2006-06-08 2007-12-21 Array Biopharma Inc. Quinoline compounds and methods of use
EP2079738A2 (en) 2006-10-27 2009-07-22 Glaxo Group Limited 7-azaindole derivatives as c-met kinase inhibitors
TW201204735A (en) * 2010-04-16 2012-02-01 Methylgene Inc Inhibitors of protein tyrosine kinase activity

Also Published As

Publication number Publication date
PL2183254T3 (pl) 2017-10-31
US20090264440A1 (en) 2009-10-22
EP2183254B1 (en) 2017-06-21
JP5656634B2 (ja) 2015-01-21
CN105777776A (zh) 2016-07-20
ES2635131T3 (es) 2017-10-02
US8389541B2 (en) 2013-03-05
RU2010111729A (ru) 2011-10-10
BRPI0816064B1 (pt) 2020-01-28
US20130165477A1 (en) 2013-06-27
CN101932586A (zh) 2010-12-29
DK2183254T3 (en) 2017-09-11
EP2183254A4 (en) 2011-09-28
TWI571468B (zh) 2017-02-21
AU2008293038A1 (en) 2009-03-05
US20120108628A1 (en) 2012-05-03
US8846927B2 (en) 2014-09-30
WO2009026717A1 (en) 2009-03-05
MY156536A (en) 2016-02-26
TW200914458A (en) 2009-04-01
AR068066A1 (es) 2009-11-04
BRPI0816064B8 (pt) 2021-05-25
BRPI0816064A2 (pt) 2015-03-31
ZA201001512B (en) 2010-11-24
CA2697795A1 (en) 2009-03-05
CN109970759A (zh) 2019-07-05
CN105777776B (zh) 2021-06-08
KR101556269B1 (ko) 2015-09-30
JP2010536887A (ja) 2010-12-02
US8404846B2 (en) 2013-03-26
RU2495044C2 (ru) 2013-10-10
AU2008293038B2 (en) 2013-08-29
CA2697795C (en) 2016-08-16
EP2183254A1 (en) 2010-05-12
IL204192A (en) 2016-08-31
KR20100075873A (ko) 2010-07-05

Similar Documents

Publication Publication Date Title
MY156536A (en) Inhibitors of protein tyrosine kinase activity
WO2008035209A3 (en) Quinoline and quinazoline derivatives as inhibitors of protein tyrosine kinase activity
MX2021013110A (es) Compuestos heterociclicos como inhibidores de la cinasa ret.
UA100262C2 (uk) Інгібітори активності протеїнтирозинкінази
PH12015501483A1 (en) Heterocyclic compounds and uses thereof
MX2010006739A (es) Compuestos pirido[2,3-b]pirazina-8-sustituidos y su uso.
MX2008012422A (es) Derivados de furano y tiofeno, pirrol substituido con pirimidinil y piridil como inhibidores de cinasa.
MX2009012772A (es) Nuevo derivado de amida para inhibir el crecimiento de celulas cancerosas.
NO20080162L (no) Tienopyrimidin og tienopyrimidinderivater som FLT-3 kinaseinhibitorer
PH12014501504A1 (en) THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES
MX342873B (es) Derivados de pirazolo-quinazolina sustituidos como inhibidores de cinasa.
EA201300556A1 (ru) Аминоспиртзамещенные производные 2,3-дигидроимидазо[1,2-с] хиназолина, пригодные для лечения гиперпролиферативных нарушений и заболеваний, связанных с ангиогенезом
MY157319A (en) Inhibitors of protein tyrosine kinase activity
TN2018000078A1 (en) 8-[6-[3-(amino)propoxy]-3-pyridyl]-1 -isopropyl-imidazo[4,5-c]quinolin-2-one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of cancer
NO20090581L (no) Hydroksylerte og metoksylerte syklopenta[D]pyrimidiner som AKT-proteinkinaseinhibitorer
TW200833341A (en) 6-aminoimidazo[1,2-b]pyridazine analogs as rho kinase inhibitors for the treatment of rho kinase-mediated diseases and conditions
PH12013501758A1 (en) Pyrazolo [1,5-a] pyridines as trk inhibitors
MX2012000166A (es) Compuestos de quinazolina que contienen fosforo y metodos de uso de los mismos.
EP1973407A4 (en) SPIRO COMPOUNDS AND METHODS OF USE
WO2008008310A3 (en) Tyrosine kinase inhibitors
NO20080168L (no) Aminoquinolin- og aminoquinoazolinkinasemodulatorer
MX2010006748A (es) Pirazolo[1,5-a]pirimidinas utiles como inhibidores de jak2.
TN2010000029A1 (en) 2, 3-dihydrobenzo[1, 4] dioxin-2-ylmethyl derivatives as alpha2c antagonists for use in the treatment of peripheric and central nervous systeme diseases
NO20080174L (no) Alkylquinolin- og alkylquinazolinkinasemodulatorer
CR20210544A (es) DERIVADOS DE 1,1-DIÓXIDO DE 3-AMINO-4H-BENZO[E][1,2,4] tiadiazina COMO INHIBIDORES DE MRGX2

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: METHYLGENE INC.

HC Change of company name or juridical status

Owner name: IGNITE RESOURCES PTY LIMITED

FG Grant or registration